| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $0 | — | -100.0% |
| Cost of Revenue | $0 | — | -100.0% |
| Gross Profit | $0 | — | +100.0% |
| R&D Expense | $2.0M | — | +29.6% |
| SG&A Expense | $1.2M | — | +35.6% |
| Operating Income | -$3.7M | — | -30.7% |
| Net Income | -$3.6M | — | -34.3% |
| EPS (Basic) | -$0.33 | — | -10.0% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $16.4M | +167.8% | +19.8% |
| Accounts Receivable | $24K | +0.0% | +181.2% |
| Inventory | $42K | +329.1% | -53.4% |
| Current Assets | $16.8M | +156.9% | +19.1% |
| Total Assets | $20.5M | +103.6% | +16.3% |
| Current Liabilities | $1.5M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$2.0M | — | +1.5% |
| Capital Expenditures | $142K | — | +1154.8% |
| Investing Cash Flow | -$254K | — | -263.4% |
| Financing Cash Flow | $12.6M | — | — |
| Free Cash Flow | -$2.2M | — | -4.8% |
| +115.1% |
| Total Liabilities | $2.7M | +22.1% | +28.2% |
| Stockholders' Equity | $17.8M | +126.1% | +14.7% |